Rani Therapeutics (NASDAQ:RANI - Get Free Report) issued its earnings results on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03), Zacks reports. The business had revenue of $1.03 million for the quarter.
Rani Therapeutics Stock Performance
NASDAQ RANI traded down $0.09 during trading on Friday, hitting $1.21. The company's stock had a trading volume of 184,819 shares, compared to its average volume of 748,422. The firm has a 50 day moving average price of $1.50 and a 200 day moving average price of $1.80. The firm has a market cap of $69.32 million, a P/E ratio of -1.14 and a beta of 0.14. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 2.34. Rani Therapeutics has a 52 week low of $1.17 and a 52 week high of $8.75.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on RANI. HC Wainwright restated a "buy" rating and issued a $9.00 target price on shares of Rani Therapeutics in a research note on Thursday. Canaccord Genuity Group restated a "buy" rating and issued a $9.00 price objective on shares of Rani Therapeutics in a report on Wednesday, February 26th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Rani Therapeutics currently has a consensus rating of "Buy" and an average target price of $12.33.
Read Our Latest Research Report on Rani Therapeutics
About Rani Therapeutics
(
Get Free Report)
Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
See Also
Before you consider Rani Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rani Therapeutics wasn't on the list.
While Rani Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
